Your Immune System Is on a Hair Trigger: Understanding Mast Cell Activation Syndrome
The Condition Behind Dozens of Unexplained Symptoms That Nobody Connected
By Krystle Alves | Naturopath, Nutritionist & Yoga Therapist | B.HSc, Adv. Dip. Naturopathy
You have been to the allergist, and the IgE panels came back unremarkable. You have been to the gastroenterologist, who found nothing definitive. The cardiologist cleared you. The dermatologist prescribed a cream. Somewhere in between you were told it might be anxiety, or IBS, or perhaps fibromyalgia. You have symptoms affecting your skin, your gut, your heart rate, your cognition, your breathing, and your mood, often simultaneously, often triggered by things that should not logically cause a reaction, food, temperature, stress, a perfume, even exercise. And every specialist has seen their piece of the picture without anyone seeing the whole.
Mast Cell Activation Syndrome is one of the most underdiagnosed conditions in functional medicine, not because it is rare, but because it is a systemic condition being assessed by a medical system organised around individual organ specialties. When the same underlying mechanism produces skin symptoms, gut symptoms, cardiovascular symptoms, neurological symptoms, and immune dysregulation all at once, no single specialist has enough of the picture to name it. Patients collect diagnoses, referrals, and prescriptions for years before anyone looks at the thread connecting them.
This post is an introduction to what MCAS actually is, how mast cells work under normal conditions, what goes wrong in the syndrome, and why it is so difficult to catch. Part two covers the stress, trauma, and genetic drivers that explain why mast cells become dysregulated in the first place, and what a functional medicine approach to actually resolving it looks like.
What Mast Cells Are and What They Are Supposed to Do
Mast cells are immune cells derived from bone marrow progenitors. Unlike most immune cells, which circulate in the blood, mast cells reside in tissue. They are found in virtually every organ in the body, positioned at the interfaces between the body and the external environment: the gut lining, the airways, the skin, the urogenital tract. They cluster near blood vessels, lymphatics, and nerves. Their location is intentional. They are sentinels, stationed at the boundaries where threats from the outside world are most likely to enter.
Each mast cell contains hundreds of granules packed with pre-formed chemical mediators, among them histamine, heparin, tryptase, chymase, and tumour necrosis factor-alpha. When a mast cell is activated, it degranulates: it releases these stored mediators into the surrounding tissue within seconds. It also synthesises and releases a secondary wave of mediators over the following minutes to hours, including prostaglandin D2, leukotrienes, interleukins (IL-4, IL-5, IL-13, IL-33), and additional cytokines.
This degranulation response is calibrated to be powerful and immediate, because mast cells are first responders. In a genuine threat situation, whether an invading pathogen, a parasite, a venomous insect sting, or a wound requiring clotting (heparin modulates the coagulation response), mast cell activation is protective and appropriate. The inflammatory cascade they trigger brings blood flow, immune cells, and clotting factors to the site of threat. The histamine they release increases vascular permeability so that immune cells can cross into tissue. The whole system is designed as a rapid, time-limited alarm response.
Mast cells are not, however, activated only by IgE-mediated allergic responses, which is the association most people and most clinicians have with them. They can be triggered by complement proteins, neuropeptides, physical stimuli (pressure, heat, cold, vibration), bacterial products, viral particles, oxidative stress, mitochondrial stress signals, hormones (particularly estrogen and corticotropin-releasing hormone, as discussed in Part Two), and a broad range of environmental chemicals and toxins. This promiscuity of activation is what makes mast cell dysregulation so clinically complex: almost anything can be a trigger.
The Cell Danger Response: When Protection Becomes the Problem
To understand how mast cells move from protective to dysregulated, the work of physician-scientist Robert Naviaux is essential. Naviaux proposed the Cell Danger Response (CDR) as a fundamental biological framework: a conserved, evolutionarily ancient programme that cells activate when they detect threat.
When a cell is under threat, whether from infection, toxin, trauma, radiation, or extreme metabolic stress, it shifts from a mode of cooperation and normal function to a mode of self-protection. Part of this shift involves releasing ATP (adenosine triphosphate, the cell's energy currency) into the extracellular space as a danger signal. Extracellular ATP is not normal. Its presence tells neighbouring cells and immune sentinels that something is wrong. Purinergic receptors on mast cells detect extracellular ATP and respond by activating.
In a healthy, acute-threat scenario, the CDR runs its course: the threat is resolved, extracellular ATP is cleared by ectoenzymes, purinergic signalling quiets, and cells return to their normal cooperative state. The mast cells stand down.
In MCAS, and in many of the chronic inflammatory and fatiguing conditions that overlap with it, the CDR does not resolve. The alarm stays on. The mast cells continue to receive danger signals, either because the original threat (an infection, a toxin, a trauma) was never fully cleared, or because the nervous system has become sensitised to threat in a way that perpetually reactivates the danger response. The mast cells are not broken. They are responding correctly to a danger signal that has not switched off. Understanding this is the difference between treating MCAS as a histamine problem and understanding it as a systemic dysregulation problem.
The CDR framework also explains something clinicians observe clinically: that MCAS is almost never found in isolation. It sits alongside dysautonomia, postural orthostatic tachycardia syndrome (POTS), hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorder (HSD), fibromyalgia, chronic fatigue syndrome, small fibre neuropathy, and interstitial cystitis at rates far above what chance would predict. All of these conditions share the same underlying thread of chronic danger signalling and nervous system sensitisation. Mast cells are central to all of them.
How MCAS Differs from Allergy and Mastocytosis
These three conditions are related but distinct, and the distinction matters for investigation.
Classic allergy is IgE-mediated. A person sensitised to a specific allergen (peanut, bee venom, latex) produces IgE antibodies that bind to the surface of mast cells and basophils. On re-exposure to the allergen, IgE cross-linking triggers degranulation. The reaction is rapid, usually within minutes, and typically reproducible. Standard allergy testing measures IgE.
Mastocytosis is a clonal disorder in which mast cells proliferate abnormally, accumulating in the skin (cutaneous mastocytosis) or in multiple organs including bone marrow, liver, and spleen (systemic mastocytosis). Mastocytosis is associated with mutations in the KIT gene, most commonly D816V, which causes the KIT receptor (the mast cell growth factor receptor) to signal constitutively, driving uncontrolled mast cell proliferation. Serum tryptase is typically substantially elevated (above 20 ng/mL) in systemic mastocytosis. It is diagnosed by bone marrow biopsy.
MCAS sits between these two. The mast cells are not clonally abnormal and do not proliferate uncontrollably, as in mastocytosis. The triggers are not necessarily IgE-mediated, as in classic allergy. Instead, mast cells are constitutionally hyperreactive: they degranulate in response to a much wider range of stimuli at much lower thresholds than normal. The mast cell population may be normal in number and histologically unremarkable, but functionally, they are on a hair trigger. And because the triggers are so diverse and the mediators released affect so many organ systems simultaneously, the symptom picture is extraordinarily broad.
The Symptom Picture: When Everything Is Affected at Once
The defining clinical feature of MCAS is multi-system involvement. This is not incidental. It is a direct consequence of the fact that mast cells are distributed throughout every organ, and that their mediators act on every tissue type.
Skin is the system where MCAS is most visibly expressed and most commonly first noticed. Flushing, particularly of the face, neck, and chest, that occurs without obvious trigger or in response to triggers that should not logically cause it. Urticaria (hives) that come and go without a consistent allergen pattern. Dermatographia, in which light scratching or pressure on the skin raises a weal response within minutes. Angioedema, the deeper swelling of the dermis and subcutaneous tissue that can affect the lips, tongue, eyelids, and hands. Generalised pruritus without rash. In some patients, a reddish-brown macular rash on the trunk that, when stroked, urticates (Darier's sign), suggests cutaneous mastocytosis as a concurrent finding.
Gastrointestinal symptoms are the second most common presentation and the most diagnostically confusing, because they are indistinguishable from IBS, GORD, gastroparesis, and inflammatory bowel disease in standard testing. Mast cells are densely distributed in the gut wall and communicate directly with the enteric nervous system. MCAS produces nausea (often significant), episodic vomiting, abdominal cramping, bloating, altered bowel habits (diarrhoea-predominant in many, constipation in some), and difficulty with food tolerance that is inconsistent and unpredictable. The reaction often occurs hours after eating rather than immediately, making food-reaction mapping unreliable without structured investigation.
Cardiovascular symptoms reflect histamine's direct effects on the heart and vasculature. H1 receptor activation produces vasodilation and hypotension. H2 receptor activation increases heart rate and myocardial contractility. The clinical result is episodes of palpitations, racing heart, low blood pressure, near-syncope or fainting (particularly on standing, producing the dysautonomia overlap), and in severe reactions, hypotensive collapse that mimics anaphylaxis without the IgE trigger. Many MCAS patients receive a POTS diagnosis before MCAS is considered, because the cardiovascular manifestations are more visible than the mast cell mechanism.
Neurological and cognitive symptoms reflect both direct mast cell mediator effects on the brain (mast cells are present in the meninges and choroid plexus, and can signal across the blood-brain barrier via cytokines) and the downstream effects of chronic systemic inflammation on neurotransmitter function. Brain fog, word-finding difficulty, memory impairment, and slowed processing are extremely common. Headaches and migraines have a well-documented mast cell and histamine component. Anxiety, and in some cases the sudden overwhelming dread described in the perimenopause article on this site as the "brain flush", can be driven by mast cell-derived histamine acting on central H1 receptors and on the locus coeruleus.
Respiratory symptoms include rhinitis, post-nasal drip, throat tightening, wheeze, and in more severe reactivity, laryngeal oedema. These often lead to an asthma diagnosis that responds incompletely to standard inhaler management.
Musculoskeletal symptoms include diffuse pain, joint pain, bone pain (heparin released by mast cells impairs bone formation over time, and histamine has direct effects on bone turnover), and fatigue that is disproportionate to any identifiable cause. The overlap with hypermobile EDS, in which connective tissue laxity appears to facilitate mast cell dysregulation, is one of the most significant clinical observations in this space.
Reproductive symptoms including severe dysmenorrhea, endometriosis (mast cells are found in ectopic endometrial tissue and contribute to the inflammatory environment that sustains it), interstitial cystitis, and pelvic pain have mast cell components that are often not considered in standard gynaecological or urological management.
The Immune System Component
Mast cells are not only alarm-sounders. They are active participants in immune regulation, and their chronic activation in MCAS has specific consequences for how the immune system is oriented.
Mast cells are positioned at the interface between innate immunity (the rapid, non-specific first response to threat) and adaptive immunity (the targeted, memory-based response that develops over days to weeks). They release cytokines that instruct the adaptive immune system in how to respond, and their cytokine profile in a chronically activated state has specific implications.
Mast cell-derived IL-4 and IL-13 drive T helper 2 (Th2) polarisation. A Th2-skewed immune environment is characterised by antibody-mediated immune responses and is associated with allergy, atopy, and parasitic resistance. It simultaneously suppresses Th1 immunity, the arm of the immune system responsible for killing intracellular pathogens, including viruses and certain bacteria. This Th2 dominance, sustained by chronically activated mast cells, helps explain why MCAS patients so frequently report recurrent infections, viral reactivations (Epstein-Barr virus, HHV-6, cytomegalovirus are commonly reported), and poor recovery from acute illness. The immune system is being steered in a direction that prioritises reactivity over pathogen clearance.
Mast cell-derived IL-6 and TNF-alpha are pro-inflammatory cytokines with far-reaching systemic effects: fever, fatigue, acute-phase protein production, and sensitisation of the nervous system to pain signals. Chronically elevated IL-6 and TNF-alpha, even at subclinical levels, produce the malaise, joint pain, cognitive impairment, and fatigue that characterise MCAS and many of the conditions that overlap with it.
The Autoimmune Link
The connection between mast cell activation and autoimmune disease is increasingly recognised in the research literature, and it operates through several overlapping mechanisms.
Mast cells produce cytokines (IL-6, IL-17, IL-33, TNF-alpha) that are among the most potent drivers of autoimmune inflammation. IL-17, in particular, is central to the pathogenesis of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Mast cells are found at elevated numbers in the synovial tissue of rheumatoid arthritis joints, in thyroid tissue in Hashimoto's thyroiditis, in salivary gland tissue in Sjögren's syndrome, and at sites of demyelination in multiple sclerosis. They are not bystanders at these sites. They are active contributors to the inflammatory tissue damage.
The Th2 skewing driven by chronic mast cell activation also creates an environment more permissive to autoimmunity. The regulatory T cell populations that normally suppress self-directed immune responses are less effective in a persistently inflammatory cytokine environment, and the loss of peripheral immune tolerance allows self-reactive lymphocytes to escape suppression.
Molecular mimicry adds another layer: when mast cells are chronically activated by microbial antigens (as in post-infectious MCAS, which can follow gastroenteritis, Lyme disease, or viral illness), the immune responses generated against those pathogens can cross-react with self-tissue antigens, initiating or accelerating autoimmune processes.
In clinical practice, the relationship between MCAS and autoimmune disease is most visibly seen in Hashimoto's thyroiditis, lupus, and rheumatoid arthritis, which are substantially overrepresented in people with confirmed or suspected MCAS. Whether MCAS drives autoimmune risk, shares underlying drivers with it, or operates as a co-factor that amplifies established autoimmune activity likely varies between patients and between conditions. What is consistent is that addressing mast cell dysregulation often reduces autoimmune inflammatory markers alongside symptom load, suggesting that the two processes are mechanistically connected.
Why Diagnosis Is So Difficult
If MCAS were straightforward to test for, this article would not need to be written. The diagnostic challenge is real, multi-layered, and has direct consequences for the years many patients spend undiagnosed.
The condition is episodic. Mast cells degranulate in response to triggers, and their mediators are cleared relatively quickly once the trigger is removed. This means that blood and urine tests taken outside of a reactive episode, or hours after one, may come back entirely normal. Testing needs to be timed to a flare, or the mast cell activity goes biochemically undetected.
Standard allergy panels test the wrong mechanism. IgE testing and skin prick testing assess IgE-mediated allergy. MCAS reactions are frequently non-IgE-mediated. A negative allergy panel does not rule out mast cell activation. This distinction is not always communicated to patients, who reasonably conclude that if their allergy tests are negative, they do not have an allergic or mast cell problem.
Serum tryptase, the most recognised mast cell marker, is often normal in MCAS. Tryptase is reliably elevated in systemic mastocytosis and in anaphylaxis (where a baseline below 11.4 ng/mL rising to above 20 ng/mL or to 1.2x baseline plus 2 ng/mL during a reaction is clinically significant). But in MCAS without clonal proliferation, tryptase may be entirely within reference range between episodes and only mildly elevated during a flare, or not at all. A normal tryptase does not exclude MCAS.
The more sensitive markers are not routinely ordered. Prostaglandin D2 and its stable urine metabolite 11-beta-prostaglandin F2-alpha are more sensitive indicators of mast cell activation than tryptase in non-mastocytosis MCAS. N-methylhistamine, the primary urinary metabolite of histamine, reflects recent histamine production more accurately than plasma histamine, which is cleared too quickly to be a reliable marker. Heparin levels can be elevated during acute mast cell episodes. Chromogranin A is a non-specific marker of neuroendocrine and mast cell activity that is elevated in some MCAS patients. These tests require timed collection (often a 24-hour urine collection), specialised processing to prevent sample degradation, and familiarity with interpretation outside the mastocytosis context.
The clinical criteria are consensus-based, not biomarker-defined. The most widely used diagnostic framework for MCAS requires three criteria to be met: first, symptoms consistent with mast cell mediator release affecting two or more organ systems; second, a clinical response to treatments that reduce mast cell activity or block mast cell mediators; and third, at least one objective laboratory finding consistent with mast cell mediator release. The reliance on treatment response as a diagnostic criterion reflects the reality that no single definitive test exists, which is clinically pragmatic but means that diagnosis depends substantially on clinical pattern recognition.
The condition is not yet taught consistently in medical training. A GP or specialist who has not specifically studied MCAS may not have it in their differential for a patient presenting with multi-system symptoms. Referrals are made to individual organ specialists, each of whom sees a partial picture. By the time a patient reaches someone with the pattern recognition to connect the dots, years may have passed and the condition develops over this time with patients limiting their diet more and more and the complication of nutrient deficiencies starts to become a real problem. I see this in the clinic time and time again.
What Clinical Investigation Actually Looks Like
Investigation for suspected MCAS requires a combination of clinical history, timed biomarker testing, and consideration of the broader clinical picture. The formal tests are generally run over a period of months; within that time, the picture starts to come together.
The most informative approach to biomarker testing is to collect samples during or immediately after a flare, before mediators are cleared. For urinary markers (N-methylhistamine, 11-beta-prostaglandin F2-alpha, leukotriene E4), a 24-hour urine collection started at the onset of a reactive episode, or collected across a period when symptoms are active, provides the most meaningful data. Serum tryptase is most informative if drawn during or within four hours of an acute episode and compared to a stable baseline. Plasma histamine has a very short half-life and is of limited utility unless collected within thirty minutes of a reaction.
Inflammatory markers including high-sensitivity CRP, IL-6, and TNF-alpha provide context around systemic inflammatory load. A comprehensive blood count may show eosinophilia (elevated eosinophils are associated with mast cell conditions and Th2 immune skewing) or monocytosis. Immunoglobulin levels and a full IgE panel assess the allergic component. Complement levels (C3, C4) evaluate complement-mediated mast cell activation.
Gut investigation adds important context, particularly in presentations where gastrointestinal symptoms are prominent. Advanced microbiome screening identifies dysbiosis patterns that perpetuate mast cell activation: histamine-producing bacterial species (certain Morganella, Klebsiella, and Hafnia strains produce significant quantities of histamine from dietary histidine) and low populations of the Lactobacillus rhamnosus and Bifidobacterium species that support histamine degradation. Intestinal permeability markers assess whether a leaky gut is contributing to systemic antigen load and ongoing mast cell stimulation.
Thyroid function and antibodies (TPO and thyroglobulin antibodies) screen for the Hashimoto's overlap that is common in MCAS. A DUTCH hormone panel evaluates the cortisol rhythm and estrogen metabolite patterns, since both cortisol dysregulation and estrogen dominance are significant mast cell activators.
If it’s suspected there is an infective origin/ trigger like glandular fever or some other viral infection, then it may be necessary to screen for antibodies, as part of a comprehensive investigation.
Genetic testing for the variants most relevant to mast cell reactivity and histamine clearance (AOC1, HNMT, MTHFR, COMT, and in selected cases TPSAB1 copy number) provides the constitutional context within which the clinical picture is unfolding. This is discussed in detail in Part Two of this post. With the major known triggers listed in Part Three. Stay tuned for those.
This Is Not a Diagnosis to Chase Down One Specialist at a Time
The patients who eventually receive an accurate MCAS picture are almost universally the ones who stopped accepting a single-system diagnosis for a multi-system condition. Not because the individual diagnoses (IBS, POTS, fibromyalgia, anxiety, chronic rhinitis) were necessarily wrong, but because each of them described a symptom cluster without explaining the mechanism connecting them.
The mechanism is mast cell hyperreactivity. The mechanism is chronic danger signalling. The mechanism is an immune system that has learned to treat ordinary stimuli as threats, and that is being maintained in that state by drivers, whether genetic, infectious, hormonal, environmental, or trauma-based, that have not yet been identified and addressed.
Part Two covers those drivers in detail, along with the genetic picture, the role of stress and trauma in perpetuating mast cell activation, and what a genuine functional medicine approach to resolution, rather than symptom management, actually involves.
This post is for educational purposes only and does not constitute medical advice. Please consult a qualified health practitioner for personalised assessment and support.
Krystle Alves is a naturopath, nutritionist and yoga therapist with over 17 years of clinical experience. She works with clients presenting with complex multi-system conditions including suspected MCAS, dysautonomia, autoimmune conditions, and chronic inflammatory presentations where standard investigation has not provided answers. Consultations are available via telehealth Australia-wide.